These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9210687)

  • 1. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS.
    Fletcher CV; Goodroad BK; Cummins LM; Henry K; Balfour HH; Rhame FS
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1571-4. PubMed ID: 9210687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
    Lambert JS; Mofenson LM; Fletcher CV; Moye J; Stiehm ER; Meyer WA; Nemo GJ; Mathieson BJ; Hirsch G; Sapan CV; Cummins LM; Jimenez E; O'Neill E; Kovacs A; Stek A
    J Infect Dis; 1997 Feb; 175(2):283-91. PubMed ID: 9203648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
    Stiehm ER; Fletcher CV; Mofenson LM; Palumbo PE; Kang M; Fenton T; Sapan CV; Meyer WA; Shearer WT; Hawkins E; Fowler MG; Bouquin P; Purdue L; Sloand EM; Nemo GJ; Wara D; Bryson YJ; Starr SE; Petru A; Burchett S
    J Infect Dis; 2000 Feb; 181(2):548-54. PubMed ID: 10669338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
    Cummins LM; Weinhold KJ; Matthews TJ; Langlois AJ; Perno CF; Condie RM; Allain JP
    Blood; 1991 Mar; 77(5):1111-7. PubMed ID: 1995097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count.
    Eyster ME; Ballard JO; Gail MH; Drummond JE; Goedert JJ
    Ann Intern Med; 1989 Jun; 110(12):963-9. PubMed ID: 2567142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
    Stiehm ER; Lambert JS; Mofenson LM; Bethel J; Whitehouse J; Nugent R; Moye J; Glenn Fowler M; Mathieson BJ; Reichelderfer P; Nemo GJ; Korelitz J; Meyer WA; Sapan CV; Jimenez E; Gandia J; Scott G; O'Sullivan MJ; Kovacs A; Stek A; Shearer WT; Hammill H
    J Infect Dis; 1999 Mar; 179(3):567-75. PubMed ID: 9952362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins.
    Pardridge WM; Buciak J; Yang J; Diagne A
    J Infect Dis; 1994 Sep; 170(3):563-9. PubMed ID: 8077712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
    Easterbrook PJ; Yu LM; Goetghebeur E; Boag F; McLean K; Gazzard B
    AIDS; 2000 Mar; 14(5):561-71. PubMed ID: 10780719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates.
    Nichols CN; Bernal I; Prince AM; Andrus L
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):49-56. PubMed ID: 11804556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.
    Prince AM; Horowitz B; Baker L; Shulman RW; Ralph H; Valinsky J; Cundell A; Brotman B; Boehle W; Rey F
    Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6944-8. PubMed ID: 3413127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus (HIV) infection in haemophiliacs: long-term prognostic significance of the HIV serologic pattern.
    Raska K; Kim HC; Raska K; Martin E; Raskova J; Saidi P
    Clin Exp Immunol; 1989 Jul; 77(1):1-6. PubMed ID: 2504517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group.
    Levy J; Youvan T; Lee ML
    Blood; 1994 Oct; 84(7):2130-5. PubMed ID: 7919326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
    Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral aspects of anti-HIV immune responses in Zairians with AIDS: lower antigenemia does not correlate with immune complex levels.
    Kashala O; Kayembe K; Kanki P; Mukeba P; Diese M; Kalengayi M; Izzia KW; Essex M
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):251-8. PubMed ID: 8471316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines.
    Nelson KE; Clements ML; Miotti P; Cohn S; Polk BF
    Ann Intern Med; 1988 Sep; 109(5):383-8. PubMed ID: 2970238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Titer of anti-P24 and anti-GP41 antibodies as a diagnostic parameter in patients with asymptomatic and symptomatic HIV infections].
    Radkowski M; Laskus T; Babiuch L; Slusarczyk J
    Pol Arch Med Wewn; 1991 Dec; 86(6):355-9. PubMed ID: 1819786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.
    Moss AR; Bacchetti P; Osmond D; Krampf W; Chaisson RE; Stites D; Wilber J; Allain JP; Carlson J
    Br Med J (Clin Res Ed); 1988 Mar; 296(6624):745-50. PubMed ID: 3126959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.